Our sister site, Drug Delivery Business News, reports today that the company agreed to integrate its twiist system with Abbott’s future glucose-ketone sensor, currently under development.
Sequel said the agreement aims to improve outcomes for people with type 1 diabetes. It adds ketone sensing capabilities to a Libre glucose sensor in combination with twiist to enable the earlier detection of rising ketones.
This marks an expansion on the integration of technologies between the two companies, as Sequel announced in March that it agreed with Abbott to make the Libre system its first continuous glucose monitor (CGM) integration for twiist. Manchester, New Hampshire-based Sequel expects to launch the combination in the second quarter of 2025. The company also recently announced integration with Senseonics’ Eversense 365 year-long implantable CGM.
Get the full story at our sister site, Drug Delivery Business News.
